# Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension.

- **DOI:** [10.3389/fimmu.2025.1502325](https://doi.org/10.3389/fimmu.2025.1502325)
- **Rating:** Strong (4.0 out of 5)
- **Verdict:** A rigorous first randomized test delivers a valuable null result, but diagnostic heterogeneity leaves efficacy in the intended population unresolved.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.3389%2Ffimmu.2025.1502325

## Key claims

1. Primary efficacy outcome was not different with lanadelumab versus placebo (1.82 vs. 1.78 attacks/month; rate ratio, 1.02; p=0.90), with attack rate reduction from baseline in both groups.
   - Support: Well-supported
   - Type: Primary finding
   - Basis: directly identified by the blinded randomized comparison and consistent sensitivity analysis
   - Location: Abstract, Results; Results, Primary Efficacy Endpoint; Table 2
2. Subgroups meeting a clinical definition of HAE showed positive attack rate reduction trend with lanadelumab versus placebo.
   - Support: Tentative
   - Type: Secondary
   - Basis: post-hoc analysis of only 18 participants with a non-significant rate ratio
   - Location: Abstract, Results; Results, Primary Efficacy Endpoint; Table 4
3. Angioedema attack rate reduction with lanadelumab was observed in CASPIAN OLE.
   - Support: Tentative
   - Type: Secondary
   - Basis: single-arm open-label extension without a concurrent control cannot identify treatment causality
   - Location: Abstract, Results; Results, CASPIAN OLE Efficacy Outcomes; Table 7
4. In patients with non-histaminergic nC1INH angioedema, lanadelumab safety was consistent with previous studies; efficacy remained inconclusive due to unmet CASPIAN primary endpoint. Overall results suggest potential clinical benefit in symptom control.
   - Support: Tentative
   - Type: Secondary
   - Basis: null randomized efficacy result with supportive evidence confined to small subgroups and an uncontrolled extension
   - Location: Abstract, Conclusion; Conclusion

## Strengths

- **First randomized evidence in population** The study addresses a documented absence of randomized prophylaxis data for non-histaminergic normal-C1-inhibitor angioedema, making its null result a meaningful addition to a sparse evidence base.
  - Dimension: contribution
  - Location: Introduction, treatment-evidence gap; Discussion, paragraph 1
- **Strong randomized trial execution chain** CASPIAN used stratified interactive-response randomization, broad blinding, a prespecified count model, FAS analysis, sensitivity analysis, and high treatment adherence. Completion was high in both randomized groups.
  - Dimension: methodological rigour
  - Location: Methods, CASPIAN and Statistical Analysis; Results, Patient Disposition and Adherence; Table 2
- **Limitations traced into interpretation** The Discussion connects possible mast-cell-mediated misclassification, high placebo response, and very small hereditary subgroups directly to the null endpoint and inability to draw definitive efficacy conclusions.
  - Dimension: positioning
  - Location: Discussion, diagnostic-classification paragraphs and limitations paragraph

## Limitations

- **Diagnostic heterogeneity dilutes target population** The idiopathic subgroup comprised 59 of 77 participants, and the paper acknowledges that antihistamine non-response may not exclude mast-cell-mediated disease. This limits what the randomized estimate establishes about bradykinin-mediated angioedema.
  - Dimension: methodological rigour
  - Location: Results, Patient Demographics; Discussion, diagnostic-complexity paragraphs
- **Hereditary subgroups remain severely underpowered** Only five participants had known mutations and thirteen had family history with unknown mutations. The numerical subgroup pattern is therefore exploratory and cannot resolve efficacy in HAE-nC1INH.
  - Dimension: contribution
  - Location: Results, Patient Demographics and Primary Efficacy Endpoint; Tables 3–4
- **Extension language exceeds causal design** The open-label extension had no concurrent control, yet the Discussion describes its before–after reductions as demonstrating a treatment effect. Regression to the mean, time trends, and the randomized-period placebo response remain alternative explanations.
  - Dimension: reporting
  - Location: Methods, CASPIAN OLE Statistical Analysis; Discussion, paragraph beginning “In CASPIAN OLE”

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The randomized counts and primary estimates are internally consistent, but interpretation of the uncontrolled extension is causally stronger than its design supports. Eligibility deviations and baseline attack-rate imbalance are disclosed and partly addressed without changing the null randomized result.
- **Research conduct:** Clean. Ethics approval, informed consent, trial registration, safety monitoring, and a specific data-access process are declared. No supplied-text conduct concern was identified.
- **Reference integrity:** Clean. 31 of 31 checkable references verified
  - 35 references in manuscript
  - 4 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17